Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

Similar articles for PubMed (Select 21681191)

1.

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.

Kohlmann A, Klein HU, Weissmann S, Bresolin S, Chaplin T, Cuppens H, Haschke-Becher E, Garicochea B, Grossmann V, Hanczaruk B, Hebestreit K, Gabriel C, Iacobucci I, Jansen JH, te Kronnie G, van de Locht L, Martinelli G, McGowan K, Schweiger MR, Timmermann B, Vandenberghe P, Young BD, Dugas M, Haferlach T.

Leukemia. 2011 Dec;25(12):1840-8. doi: 10.1038/leu.2011.155. Epub 2011 Jun 17.

PMID:
21681191
2.

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, Dicker F, Schnittger S, Dugas M, Kern W, Haferlach C, Haferlach T.

J Clin Oncol. 2010 Aug 20;28(24):3858-65. doi: 10.1200/JCO.2009.27.1361. Epub 2010 Jul 19.

3.

Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.

Bernard V, Gebauer N, Dinh T, Stegemann J, Feller AC, Merz H.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1667-76. eCollection 2014.

4.

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, Przychodzen B, Mian SA, Nasser EE, Shooter C, Westwood NB, Strupp C, Gattermann N, Maciejewski JP, Germing U, Mufti GJ.

Blood. 2010 Nov 11;116(19):3923-32. doi: 10.1182/blood-2010-03-274704. Epub 2010 Aug 6.

5.

KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics.

Rechsteiner M, von Teichman A, Rüschoff JH, Fankhauser N, Pestalozzi B, Schraml P, Weber A, Wild P, Zimmermann D, Moch H.

J Mol Diagn. 2013 May;15(3):299-311. doi: 10.1016/j.jmoldx.2013.02.001. Epub 2013 Mar 24.

6.

RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.

Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, Lambertenghi Deliliers G, Beran M, Onida F.

Clin Cancer Res. 2010 Apr 15;16(8):2246-56. doi: 10.1158/1078-0432.CCR-09-2112. Epub 2010 Apr 6.

7.

Integration of next-generation sequencing into clinical practice: are we there yet?

Kohlmann A, Grossmann V, Haferlach T.

Semin Oncol. 2012 Feb;39(1):26-36. doi: 10.1053/j.seminoncol.2011.11.008. Review.

PMID:
22289489
8.

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.

Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN, Beyne-Rauzy O, Stamatoulas A, Dreyfus F, Ifrah N, de Botton S, Vainchenker W, Bernard OA, Birnbaum D, Fontenay M, Solary E; Groupe Francophone des Myélodysplasies.

Haematologica. 2009 Dec;94(12):1676-81. doi: 10.3324/haematol.2009.011205. Epub 2009 Oct 1.

9.

TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.

Martínez-Avilés L, Besses C, Álvarez-Larrán A, Torres E, Serrano S, Bellosillo B.

Ann Hematol. 2012 Apr;91(4):533-41. doi: 10.1007/s00277-011-1330-0. Epub 2011 Sep 9.

PMID:
21904853
10.

Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions.

de Biase D, Visani M, Baccarini P, Polifemo AM, Maimone A, Fornelli A, Giuliani A, Zanini N, Fabbri C, Pession A, Tallini G.

PLoS One. 2014 Feb 4;9(2):e87651. doi: 10.1371/journal.pone.0087651. eCollection 2014.

11.

Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Muramatsu H, Makishima H, Jankowska AM, Cazzolli H, O'Keefe C, Yoshida N, Xu Y, Nishio N, Hama A, Yagasaki H, Takahashi Y, Kato K, Manabe A, Kojima S, Maciejewski JP.

Blood. 2010 Mar 11;115(10):1969-75. doi: 10.1182/blood-2009-06-226340. Epub 2009 Dec 11.

12.

The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR.

Kobunai T, Watanabe T, Yamamoto Y, Eshima K.

Biochem Biophys Res Commun. 2010 Apr 23;395(1):158-62. doi: 10.1016/j.bbrc.2010.03.167. Epub 2010 Mar 31.

PMID:
20361930
13.

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.

PMID:
19096301
14.

Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.

Park HD, Lee SH, Sung KW, Koo HH, Jung NG, Cho B, Kim HK, Park IA, Lee KO, Ki CS, Kim SH, Yoo KH, Kim HJ.

Ann Hematol. 2012 Apr;91(4):511-7. doi: 10.1007/s00277-011-1326-9. Epub 2011 Sep 8.

PMID:
21901340
15.

Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.

Grossmann V, Schnittger S, Schindela S, Klein HU, Eder C, Dugas M, Kern W, Haferlach T, Haferlach C, Kohlmann A.

J Mol Diagn. 2011 Mar;13(2):129-36. doi: 10.1016/j.jmoldx.2010.09.001.

16.

Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).

Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J.

J Thorac Oncol. 2011 Jun;6(6):1006-15. doi: 10.1097/JTO.0b013e318211dcee.

PMID:
21532509
17.

Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.

Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P, Han Y, Hsieh FH, Sekeres MA, Mali RS, Kalaycio M, Lichtin AE, Advani AS, Duong HK, Copelan E, Kapur R, Olalla Saad ST, Maciejewski JP, Tiu RV.

PLoS One. 2012;7(8):e43090. doi: 10.1371/journal.pone.0043090. Epub 2012 Aug 15.

18.

Robustness of amplicon deep sequencing underlines its utility in clinical applications.

Grossmann V, Roller A, Klein HU, Weissmann S, Kern W, Haferlach C, Dugas M, Haferlach T, Schnittger S, Kohlmann A.

J Mol Diagn. 2013 Jul;15(4):473-84. doi: 10.1016/j.jmoldx.2013.03.003. Epub 2013 May 14.

19.

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples.

Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ, Luthra R.

Mod Pathol. 2009 Aug;22(8):1023-31. doi: 10.1038/modpathol.2009.59. Epub 2009 May 8.

20.

KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.

Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, Snijders PJ, Thunnissen E, Zwarthoff EC.

J Mol Diagn. 2012 May-Jun;14(3):247-55. doi: 10.1016/j.jmoldx.2012.01.011. Epub 2012 Mar 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk